Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Representative cell cycle flow cytometry scatter plots for NIH/3T3 cells after 24-hour treatment with IGF-1 formulations.
  • Fig. S2. 1H NMR spectra of PEGylated dendrimer panel (without IGF-1).
  • Fig. S3. MALDI-TOF mass spectra for partially PEGylated dendrimer screen.
  • Fig. S4. Complete uptake data for partially PEGylated dendrimers into bovine cartilage explants.
  • Fig. S5. Complete CHON-001 cellular viability data for partially PEGylated dendrimers at a range of doses of dendrimers.
  • Fig. S6. Desorption of PEGylated dendrimers in solutions of different ionic strengths.
  • Fig. S7. Quantification of ex vivo bovine cartilage tissue viability staining in Fig. 2.
  • Fig. S8. Histology (H&E) of representative sections from likely contact organs for ~5- to 10-nm materials.
  • Fig. S9. Histology (H&E) of rats treated with dendrimers having suboptimal percentage of end group PEGylation.
  • Fig. S10. 3D reconstruction of multiphoton microscopy images of full-thickness cartilage from intact rat femurs harvested 2 days after injection of free IGF-1.
  • Fig. S11. Penetration of cartilage explants in DMEM (no protein in media).
  • Table S1. Characterization of percentage of PEGylation by NMR integral ratios.
  • Table S2. Characterization of percentage of PEGylation by mass addition according to MALDI-TOF data.
  • Table S3. Serum toxicology markers at 2 and 7 days after intra-articular injection of Gen 6 45% PEG–IGF-1.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S4 (Microsoft Excel format). Individual subject-level data for Fig. 2D and fig. S5.